Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

EDITOR:
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.

JNCCN:
Kimberly Callan, MS, Senior Director, Professional and Patient Publications, NCCN, has disclosed that she has no relevant financial relationships.
Genevieve Hartzman, MA, Journal Production Specialist, NCCN, has disclosed that she has no relevant financial relationships.

CE PLANNERS:
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships. (Employed by NCCN until 2/17/17)
Karen Kanefield, Manager, Continuing Education Accreditation and Program Operations, has disclosed that she has no relevant financial relationships.
Kathy Smith, Manager, CE Grant Writing & Project Management, NCCN, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Director, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
Al B. Benson III, MD, Panel Chair, has disclosed that he receives grant/research support from Advanced Accelerator Applications SA, Alchemia, Amgen Inc., Gilead, and Novartis Pharmaceuticals Corporation; receives consulting fees/honoraria from Astellas and Aveo; and is a scientific advisor for Bayer HealthCare, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Inc., Genomic Health, Inc., Lilly/Imclone, Merck & Co., Inc., NCI, Precision Therapeutics, Inc., sanofi-aventis U.S., Spectrum, and Vicus.
Michael I. D’Angelica, MD, Panel Vice Chair, has disclosed that he has no relevant financial relationships.
Daniel E. Abbott, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Daniel B. Brown, MD, Panel Member, has disclosed that he is on the product/speakers’ bureau for Boston Scientific; receives consulting fees/honoraria from Cook Medical; and receives grant/research support from Sirtex Medical.
Daniel T. Chang, MD, Panel Member, has disclosed that he receives consulting fees/honoraria, grant/research support, and salary from Varian Medical Systems, Inc.; and receives equity interest/stock options from ViewRay, Inc.
Anne M. Covey, MD, Panel Member, has disclosed that she is a scientific advisor for Accurate Medical.
R. Kate Kelley, MD, Panel Member, has disclosed that she has no relevant financial relationships.
Manisha Palta, MD, Panel Member, has disclosed that she receives other financial benefit from Oakstone CME.
Vaibhav Sahai, MD, MS, Panel Member, has disclosed that he receives consulting fees/honoraria from Celgene Corporation and NewLink Genetics; receives grant/research support from Celgene Corporation; and is a scientific advisor for Celgene Corporation and Merrimack.
Jean-Nicolas Vauthey, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Karin G. Hoffmann, RN, CCM, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships.
Susan Darlow, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.